Adimab Reports Strong Partnering Year for 2025 [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
LEBANON, N.H. Jan. 12, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations. Since 2009, Adimab has partnered with over 140 companies to discover therapeutic drug candidates. New alliances for 2025 include collaborations with Central Therapeutics, Enara Bio, Onco3R, Roivant, Variant Bio, and Triptych, among others. In addition, Adimab expanded its collaborations with 12 partners, including Alnylam, 3T Biosciences, Compugen, Cullinan Therapeutics, Lilly, Regeneron, RedRidge, and Therini, among others. In 2025, Adimab and its partners initiated discovery on 75 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to more than 650. Many partners retain the contractual rights to
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $530.00 to $529.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Needham & Company LLC from $520.00 to $529.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website